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 2 
Abstract 15 
Peste des petits ruminants (PPR) is a severe disease of goats and sheep that is widespread in Africa, 16 
the Middle East and Asia. Several effective vaccines exist for the disease, based on attenuated 17 
strains of the virus (PPRV) that causes PPR. While the efficacy of these vaccines has been 18 
established by use in the field, the nature of the protective immune response has not been 19 
determined. In addition, while the vaccine derived from PPRV/Nigeria/75/1 (N75) is used in many 20 
countries, those developed in India have never been tested for their efficacy outside that country. 21 
We have studied the immune response in goats to vaccination with either N75 or the main Indian 22 
vaccine, which is based on isolate PPRV/India/Sungri/96 (S96). In addition, we have compared the 23 
ability of these two vaccines, in parallel, to protect animals against challenge with pathogenic 24 
viruses from the four known genetic lineages of PPRV, representing viruses from different parts of 25 
Africa as well as Asia. These studies showed that, while N75 elicited a stronger antibody response 26 
than S96, as measured by both ELISA and virus neutralisation, S96 resulted in more pronounced 27 
cellular immune responses, as measured by virus antigen-induced proliferation and interferon 28 
gamma production. While both vaccines induced comparable numbers of PPRV-specific CD8
+
 T 29 
cells, S96 induced a higher number of CD4
+
 T cells specifically responding to virus. Despite these 30 
quantitative and qualitative differences in the immune responses following vaccination, both 31 
vaccines gave complete clinical protection against challenge with all four lineages of PPRV. 32 
Importance: Despite the widespread use of live attenuated PPRV vaccines, this is the first 33 
systematic analysis of the immune response elicited in small ruminants. These data will help in the 34 
establishment of the immunological determinants of protection, an important step in the 35 
development of new vaccines, especially DIVA vaccines using alternative vaccination vectors. This 36 
study is also the first controlled test of the ability of the two major vaccines used against virulent 37 
PPRV strains from all genetic lineages of the virus, showing conclusively the complete cross-38 
protective ability of these vaccines.  39 
  40 
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 3 
Introduction 41 
Peste des petits ruminants virus (PPRV) causes a severe disease of sheep and goats (PPR) and has 42 
been spreading extensively over the past two decades; it is now found widely distributed through 43 
large parts of Africa, the Middle East and Asia, posing an increasing threat to poor livestock 44 
keepers, primarily in developing countries (1-4). PPRV is a negative-strand RNA virus, a 45 
paramyxovirus of the genus Morbillivirus, related to the human pathogen measles virus (MV), as 46 
well as other animal pathogens such as canine distemper virus (CDV) and the now-eradicated 47 
rinderpest virus (RPV). Control of PPR has recently become a major international goal, marked by 48 
the adoption in 2014 of a resolution by the World Organisation for Animal Health (OIE) to 49 
establish a control programme with a view to eventual eradication of the disease (5). 50 
As with other morbilliviruses, such as MV and RPV, there is no evidence of serotypes within 51 
PPRV, although sequence-based phylogenetic analysis has divided the known isolates into 4 genetic 52 
lineages (6, 7), with lineages I-III found in different parts of sub-Saharan Africa, while all Asian 53 
and almost all Middle Eastern isolates belong to lineage IV. The genetic distances between the 54 
lineages are relatively small, as illustrated by the phylogenetic tree shown in Fig 1, which is based 55 
on the available full-length genome sequences (after removing all but one from each group of very 56 
similar sequences). Although PPR was first described as a unique disease in West Africa (8) and 57 
PPRV was first recognised as a separate virus in samples from East Africa (9), the virus probably 58 
originates in Asia (10), as did RPV, both viruses showing the same pattern of a single lineage 59 
covering Asia and the Middle East, with separate lineages appearing in Africa. In recent years, 60 
lineage IV viruses have also begun to appear in sub-Saharan Africa (11); an example of such an 61 
African lineage IV virus can be seen in PPRV/Nigeria/2013 in Fig 1. In general, lineage II is the 62 
most similar to lineage IV, with lineages I and III forming a separate subgroup (Fig 1); lineage I 63 
viruses are now uncommon, and appear to be being replaced in West Africa by lineage II and 64 
lineage IV viruses.  65 
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 4 
Disease control is mostly achieved through the use of clinical or laboratory-based diagnosis coupled 66 
with vaccination and/or slaughter. All the vaccines currently in use are live attenuated strains of 67 
PPRV (12, 13), the two most commonly used being derived from PPRV/Nigeria/75/1 (12) (a 68 
lineage II isolate) or PPRV/India/Sungri/96 (14) (a lineage IV isolate). The Nigeria/75 (N75) 69 
vaccine is used in most countries outside India, while the Sungri/96 (S96) vaccine is used only in 70 
India. While both vaccines have provided lasting protection in field use, there has been no explicit 71 
testing of either vaccine against the full range of existing wild type viruses. In particular, the S96 72 
vaccine has only been shown experimentally to protect against two Indian isolates (15), and has 73 
been tested for neutralisation only of itself (15, 16). The N75 vaccine has been shown, in different 74 
studies, to protect against virus isolates of all four lineages (12, 17-19), but serum neutralisation 75 
titre was again determined only against the vaccine itself, and we lack information on cell-mediated 76 
(T cell) responses in sheep/goats treated with either vaccine. This comparative lack of information 77 
has led to some workers suggesting a need for further vaccine strains to be developed based on local 78 
isolates (e.g. 20). We have therefore directly compared the protection given by these two vaccines 79 
against representative wild type challenge viruses from all four lineages. Establishing their 80 
universal efficacy would not only prevent wasted effort in making further vaccine strains, but 81 
improve the flexibility of supply of vaccine during the global eradication campaign by showing that 82 
supplies of either vaccine can be used in any country needing to vaccinate its small ruminant 83 
population. In addition, there is little information as to the range of immune responses elicited by 84 
these vaccines, the primary test of vaccine efficacy being a functional one of protection against 85 
virulent challenge. We have therefore examined the antibody and T cell responses elicited by 86 
vaccination of goats with either N75 and S96, data which will provide the foundation for future 87 
work on establishing the basis of protection provided by these vaccines. 88 
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 5 
Materials and Methods 89 
Viruses, including vaccines 90 
All virus stocks were cultured in Vero cells expressing canine signalling lymphocyte activation 91 
marker (SLAM), the morbillivirus receptor (Vero-Dog-SLAM; VDS) (21). The vaccine viruses 92 
used were recombinant PPRV/Nigeria/75/1 (22) and PPRV/India/Sungri/96 vaccine (14), the 93 
original stock of which was the gift of MSD Animal Health. In order to eliminate any effect of 94 
differences in the way the two vaccines were prepared, the vaccine stocks were grown and titred in 95 
our laboratory, using the same cell stocks, media and processing. They were passaged 1-2 times 96 
from rescue (N75) or from the original commercial stock (S96). For serum neutralisation tests we 97 
used the same viruses. Field isolates used and their passage history since last isolated from an 98 
animal were PPRV/Nigeria/76/1 (BK6/V3/VDS1), PPRV/Sudan/Sennar/72 (BK1/LK1/V2/VDS1), 99 
PPRV/Ivory Coast/89 (VDS1), and PPRV/Ghana/78 (LK1/V1/VDS1), all of which were from the 100 
Pirbright Institute virus archive, and PPRV/Iran/2011 (originally called PPRV/Kurdistan/2011; 101 
(23)) (CV1-S1/VDS2), the kind gift of Dr Bernd Hoffman, FLI, Germany. Virus stocks were grown 102 
and titred on VDS as previously described (24). 103 
Vaccination/challenge protocol 104 
All animal studies were carried out under licenses PPL 70/7199 and PPL70/8833 issued by the 105 
Home Office of the United Kingdom in accordance with relevant legislation and after approval by 106 
the Pirbright Institute Animal Welfare and Ethical Review Board. Outbred goats were sourced from 107 
commercial farms. Animals entered the secure isolation units 7 days before the start of the 108 
procedure to acclimatise to the new husbandry regime, and were provided with daily enrichment 109 
during the trials. 110 
The core study, in which animals were vaccinated using live PPRV vaccines, and then challenged 111 
with a wild type virus, was repeated five times, once for each wild type virus. In each core study, 112 
two groups of goats (9 to 12 months old), each consisting of five animals, were inoculated with a 113 
standard dose (2x10
4
 50% tissue culture infectious doses [TCID50] determined in VDS cells [VDS 114 
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 6 
TCID50], equivalent to 10
3
 TCID50 determined in Vero cells) of S96 or N75, given subcutaneously. 115 
Two cohoused animals were left unvaccinated to act as controls for the challenge virus. After 4 116 
weeks, all the animals were infected with 2x10
5
 VDS TCID50 of challenge virus. Blood samples 117 
were collected on various days post-vaccination (dpv) and post-challenge (dpc) for different assays. 118 
In the first vaccination/challenge study carried out (PPRV/Ivory Coast/89) this challenge was given 119 
intranasally; however, there was concern that it was more difficult to exactly control the dose of 120 
challenge virus administered to each animal using this route. To ensure uniformity of the challenge 121 
in each animal, and since our previous studies had not identified any difference in the disease 122 
elicited by virus administration intranasally or by injection (24), the remainder of the challenges 123 
were given subcutaneously.  124 
Clinical scores for PPR disease were calculated based on rectal temperatures and other clinical 125 
signs. A score of 1 was given for rectal temperatures 0.1 to 2˚C above normal for the animal, and a 126 
score of 2 was given for temperatures >2˚C above normal. Similarly, a score of 1 was given for 127 
ocular or nasal congestion, congestion of the gums, a soft stool, a cough or apathetic behaviour; a 128 
score of 2 was given for visible ocular or nasal discharge, 1 to 2 lesions in the gums, watery 129 
diarrhoea, or reluctance to walk or stand; a score of 3 was given for necrotic oral lesions. The 130 
cumulative score on each day was recorded as the final clinical score. Animals reaching clearly 131 
defined humane endpoints of a moderate severity were euthanised humanely. 132 
Assays for anti-PPRV antibodies 133 
Serum samples were obtained from goats by venepuncture into plain vacutainers. After clotting, the 134 
tubes were centrifuged at 2,000xg for 20 mins and the serum removed and either stored at -80˚C or 135 
heat-treated at 56˚C for two hours (inactivating both complement and any remaining virus) and then 136 
stored at -20˚C. Antibodies specific for PPRV proteins were measured using the N protein-specific 137 
competition ELISA (cELISA) kit available from ID Vet, Garbles, France, or the H protein-specific 138 
cELISA developed at the Pirbright Institute (25); sera were assayed in duplicate (N protein 139 
cELISA) or triplicate (H protein cELISA) and results calculated in accordance with the 140 
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 7 
manufacturers' instructions. Statistical analysis was based on the mean of technical replicates. 141 
Neutralising titres against N75 and S96 were determined in VDS cells as previously described (26); 142 
the titre was taken to be the reciprocal of the dilution at which 50% of wells showed no cytopathic 143 
effect, and was calculated using the Spearman-Kärber method (27). 144 
Preparation of peripheral blood mononuclear cells (PBMCs) 145 
PBMCs were prepared from heparinised goat blood obtained by venepuncture. Approximately 30ml 146 
heparinised blood was mixed with 20ml Dulbecco's PBS (ThermoFisher) then layered over 15ml 147 
Ficoll Paque PLUS (GE Healthcare) in Leucosep tubes prepared according to manufacturer’s 148 
instructions (Greiner). These gradients were centrifuged at 800xg for 20 minutes at 20˚C with no 149 
brake. Mononuclear cells above the polyethylene barrier were collected and washed in Hank’s 150 
Balanced Salt Solution (HBSS), resuspended in 10ml 1X RBC Lysis Buffer (Santa Cruz) and 151 
incubated at room temperature for 5 minutes. Following centrifugation at 330xg for 5 minutes, the 152 
cells were washed once more in 10ml HBSS and resuspended in 10ml RPMI-1640 (ThermoFisher) 153 
supplemented with 5% (v/v) foetal bovine serum (FBS), 1 x MEM Non-Essential Amino Acid 154 
Solution (ThermoFisher), 1mM sodium pyruvate (ThermoFisher), 0.5μg/ml gentamicin (Sigma) 155 
and 50μM 2-mercaptoethanol (Sigma) (proliferation medium). Viable PBMC counts were 156 
determined by Trypan Blue exclusion using a Nexelom T4 automated cell counter and the cells 157 
either used immediately or stored frozen over liquid nitrogen in 90% FBS/10% DMSO until used. 158 
For use, cryopreserved cells were thawed quickly in a 37˚C water bath, diluted slowly with 4 159 
volumes of proliferation medium pre-warmed to 37˚C, then rapidly diluted with a further 4 volumes 160 
of medium. The cells were pelleted at 330 x g for 10 mins, washed with a further 10 ml of 161 
proliferation medium and finally resuspended in proliferation medium before counting viable cells. 162 
We did not observe any consistent difference between the results of assays with frozen and fresh 163 
cells. Fresh cells were used for all flow cytometric analyses of T cell interferon gamma responses; 164 
fresh cells were used for T cell proliferation studies on all samples from the set of vaccinates 165 
challenged with PPRV/Sudan/Sennar/72 and on almost all samples from the set of vaccinates 166 
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 8 
challenged with PPRV/Nigeria/76/1, with the exception of samples from 7 dpc; T cell proliferation 167 
studies on samples from the set of vaccinates challenged with PPRV/Iran/2011were all done on 168 
cryopreserved cells. 169 
Preparation of labelled antibodies 170 
Mouse monoclonal antibodies (mAbs) were conjugated to AlexaFluor488 using the specific 171 
antibody labelling kit (ThermoFisher), while mAb conjugation with other fluorochromes 172 
(allophycocyanin (APC), R-phyco-erythrin (RPE)) was carried out using Lightning Link kits 173 
(Innova Biosciences); in all cases the manufacturers' instructions were followed directly. 174 
Conjugated antibodies were titrated on goat PBMCs before use to determine the optimal working 175 
concentration and were stored at 4˚C. The antibodies used were: anti-CD8 (clone CC58; (28)); anti-176 
CD4 (clone 17D (ECACC 91060551); (29)); isotype control antibodies TRT1 and TRT3 (30). 177 
Antigen preparations for T cell response assays  178 
To generate crude virus antigen preparations 10 x 175cm
2
 flasks of VDS were infected with either 179 
PPRV Nigeria/75/1 or PPRV Sungri/96 at a multiplicity of infection (MOI) of 0.1 and incubated at 180 
37˚C, 5% CO2 until CPE was extensive (usually 2-3 days). The same number of uninfected cells 181 
were processed identically to produce negative control VDS antigen. Preparation of virus antigens 182 
from the infected and control cell pellets was carried out as previously described (26). Protein 183 
concentration was determined by Coomassie (Bradford) Protein Assay kit (ThermoFisher). Antigen 184 
was diluted to 1mg/ml in 10% sucrose/PBS and aliquots of this antigen were stored at -20˚C. 185 
Preparations of virus or heat inactivated(HI)-virus for use in T cell response assays were tissue 186 
culture supernatants from similarly infected or non-infected VDS, used either directly or following 187 
heat inactivation at 56˚C for 2 hours. 188 
T cell proliferation assay 189 
Thymidine incorporation assays were carried out essentially as previously described (26) except 190 
that some assays were performed on cryopreserved cells; PBMCs (2x10
5
) were plated in 96 well U 191 
bottomed plates and exposed in quadruplicate wells to each of the following PPRV and control 192 
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 9 
antigen preparations: medium only, 5μg/ml Concanavalin A (Con-A; Sigma-Aldrich), 20μg/ml 193 
VDS cell control antigen, 20μg/ml N75 antigen, 20μg/ml S96 antigen, 1:2 dilution of HI-N75, HI-194 
S96 or a HI-VDS cell mock virus preparation. Cells were incubated at 37˚C, 5% CO2 for 5 days, 195 
then 0.037 MBq 
3H thymidine (Perkin Elmer) in 30μl RPMI-1640 was added per well and cells 196 
were incubated overnight at 37˚C, 5% CO2. Cells were harvested onto pre-wet glass fibre filter mats 197 
(Perkin Elmer) using an automated harvester. The filter mats were dried before being sealed in 198 
sample bags with 3.5ml BetaScint scintillation liquid (Perkin Elmer). Scintillation counts were 199 
recorded using a 1450 MICROBETA TriLux (Wallac) and MicroBeta Windows Workstation 200 
V4.70.05 software. Stimulation indices (SI) were calculated by dividing the mean counts per minute 201 
(cpm) for cells incubated with specific antigen by the mean cpm for cells incubated with the mock 202 
antigen. 203 
Flow cytometric analysis of T cell interferon gamma responses 204 
PBMCs (1x10
6
) were plated in 96 well U bottomed plates and incubated in triplicate wells with 205 
each of the following PPRV and control preparations: medium only, 5μg/ml pokeweed mitogen 206 
(PWM; Sigma Aldrich), 20μg/ml VDS cell control antigen, 20μg/ml N75 antigen, 20μg/ml S96 207 
antigen, VDS cell-derived mock virus, live N75 virus and live S96 virus, all added in a 100μl 208 
volume per well. Cells were incubated at 37˚C, 5% CO2 overnight, the protein transport inhibitor 209 
BD Golgi Plug
TM
 was added to all wells at 1μl/ml in 30μl RPMI-1640 and cells incubated for a 210 
further 6 hours at 37˚C, 5% CO2. Cells were pelleted at 330xg for 5 minutes and washed twice with 211 
100μl DPBS (ThermoFisher). Directly conjugated antibodies APC-labelled anti-CD4 and RPE-212 
labelled anti-CD8 were added along with 0.5μl per well Zombie AquaTM dead cell stain (Biolegend) 213 
and the cells incubated incubated at 4˚C for 30 minutes in the dark. The cells were again pelleted 214 
and washed once in DPBS before fixation with BD Cytofix/Cytoperm
TM
 Buffer (BD Biosciences) 215 
containing 4.2% formaldehyde, at 4˚C for 30 minutes in the dark. Cells were again pelleted and 216 
washed once in DPBS before being stored overnight in 100μl DPBS at 4˚C. The following morning 217 
the cells were pelleted and permeabilised with 100μl BD Perm/Wash Buffer (BD Biosciences) for 218 
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 10 
20 minutes at 4˚C in the dark. Cells were incubated with 100μl/well anti-IFN-γ conjugated with 219 
AlexaFluor488 (clone CC302, Bio-Rad Antibodies) diluted 1/320 in BD Perm/Wash Buffer and 220 
incubated for 30 minutes at 4˚C in the dark. The cells were washed twice with 150μl/well BD 221 
Perm/Wash Buffer before finally being re-suspended in 200μl MACS Wash Solution (Miltenyi 222 
Biotec). Data was collected with a MACSQuant 10 Analyzer (Miltenyi Biotec) using 223 
MACSQuantify software. A sample of 150μl of the 200μl per well was analysed to enable 224 
assessment of rare events. Single-labelled cells were used for multi-colour compensation for every 225 
experiment. All flow cytometry raw data files were analysed in FlowJo X; the gating strategy used 226 
is shown in Fig 2. 227 
Detection of PPRV RNA 228 
Reverse transcription-real-time PCR (RT-qPCR) for the detection of PPRV RNA was carried out in 229 
the Nonvesicular Reference Laboratory at the Pirbright Institute using the method of Batten et al 230 
(31). 231 
Construction of phylogenetic tree 232 
To construct the phylogenetic tree shown in Fig 1, all the full length PPRV genomes available in 233 
GenBank were assembled and aligned. Where two or more genomes were essentially identical 234 
(genetic distance < 0.001), all but one of the sequences were removed from the alignment. The tree 235 
was calculated and plotted using MEGA6 (32); the evolutionary history was inferred using the 236 
Maximum Likelihood method based on the General Time Reversible model (33) with a discrete 237 
Gamma distribution to model evolutionary rate differences among sites and a rate variation model 238 
which allowed for some sites to be evolutionarily invariable. This model (GTR+G+I) was 239 
determined to be the optimal model using jModelTest (34). The final analysis involved 40 240 
nucleotide sequences and 15948 positions; all positions with less than 80% site coverage were 241 
eliminated, that is, fewer than 20% of alignment gaps, missing data, and ambiguous bases were 242 
allowed at any position. The reliability of the tree topology was determined by bootstrap using 500 243 
replicates. 244 
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 11 
Statistical analysis 245 
Statistical analysis was carried out using programs available in R (35). Data were analysed using 246 
mixed models in which vaccine and time were fixed factors and individual animals were random 247 
factors. Although different batches of vaccination were carried out at different times, the group of 248 
vaccinations was not considered a significant factor, since any effects would be included in 'animal'. 249 
For analysis of cELISA and proliferation data following challenge with wild type virus, the 250 
challenge virus was a third fixed factor. Temperature profiles and clinical score data were analysed 251 
separately for each challenge experiment. Temperature profiles were fit to linear models as fourth 252 
order polynomials with respect to time. Clinical scores were compared as the mean score for each 253 
animal over the days it was alive to be assessed, using a non-parametric one-way analysis with 254 
multiple comparisons, nparcomp (36). Linear models were fit using nlme (37) and comparisons 255 
carried out using lsmeans (38), with appropriate correction for multiple comparisons. In order to 256 
improve the normality of the data, virus neutralisation titres and T cell proliferation data were 257 
analysed as the log2(titre) or log2(stimulation index), respectively.  258 
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Results 259 
In total, five rounds of studies were conducted, in each of which 5 animals were vaccinated with 260 
N75, 5 with S96 and two left unvaccinated to validate the pathogenicity of the challenge virus used. 261 
Partial results from the first study carried out, using challenge with PPRV/Ivory Coast/89, have 262 
previously been published (26); those results are included here for completeness and to provide the 263 
maximum power to our analysis of the response to the vaccine. In each round of studies, the 10 264 
vaccinates and two control animals were infected with a representative isolate from lineage I, II, III 265 
or IV at 28 dpv to assess protection; when it was observed that the challenge virus selected from 266 
lineage II (PPRV/Nigeria/76/1) gave only very mild disease, a further group of animals was 267 
vaccinated and challenged using a more virulent challenge virus from the same lineage 268 
(PPRV/Ghana/78). One N75 vaccinate in one study was removed due to an unrelated underlying 269 
health issue. While this gave a total of 24 or 25 animals vaccinated with, respectively, N75 or S96, 270 
limitations in obtained material or processing time required that certain antibody or cell-based 271 
assays were carried out using a representative number of samples. In all the following data, the 272 
numbers of experimental animals on which the analysis is based are given in the respective figure 273 
legends. 274 
Antibody responses to vaccination 275 
The most commonly used way to assess the antibody responses to vaccination with live PPRV 276 
vaccines, is to use the commercially available competition ELISA (cELISA) kits, which measure 277 
antibodies directed to the viral nucleocapsid (N) protein (39) or the viral surface attachment (H) 278 
protein (25). For both of these assays, the viral antigen used to coat the ELISA plates is based on 279 
the N75 vaccine. As can be seen in Fig 3, vaccination with either N75 or S96 gave rise to antibodies 280 
that reacted strongly in either cELISA. Animals vaccinated with N75 had slightly stronger 281 
responses (showed greater competition) in the N protein cELISA (Fig 3a), statistically significant at 282 
7, 14, 21 and 28 days post-vaccination (dpv) (p=0.006, 0.003, 0.01 and 0.0004 respectively). The 283 
antibody response as measured in the H protein cELISA appeared to develop slightly more slowly 284 
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 13 
(Fig 3b), with no significant detection of anti-H antibodies in sera from either group of vaccinates at 285 
7 dpv. However, thereafter both groups showed clear increases in anti-H antibodies, with sera from 286 
N75 vaccinates again showing greater competition than sera from S96 vaccinates (p≤0.0001 for this 287 
comparison at 14, 21 and 28 dpv). 288 
An alternative way of quantifying development of anti-virus antibody is to determine the ability of 289 
sera to prevent virus infection of susceptible cells, expressed as the virus neutralisation titre. As this 290 
assay is more time consuming, it was only performed for three sets (i.e. 15 animals for each group 291 
of vaccinates). An advantage of this assay is that, not being confined to a specific kit with antigen 292 
derived from only N75, all sera could be tested for the ability to neutralise both N75 and S96 293 
viruses, i.e. both homologous and heterologous neutralisation. Since it was reasonable to assume a 294 
zero titre for unvaccinated animals in the UK (and a selection of day 0 sera indeed showed no effect 295 
on virus infection), and since the cELISA data suggested that the neutralising titre at 7 dpv would 296 
also be very low, we assayed the neutralisation titre in samples taken at 14, 21 and 28 dpv.  297 
These studies showed that N75 vaccinates had a higher titre against N75 virus than did the S96 298 
vaccinates at all the time points assayed (Fig 3c) (p<0.0001). Interestingly, this group of vaccinates 299 
also had a higher titre against S96 virus at 14 dpv (p<0.0001), though this difference disappeared by 300 
21 dpv (Fig 3d). In general, the N75 vaccinates seemed to have reached their maximum titre against 301 
either target virus by 14 dpv, while the neutralising titres in the sera from the S96 vaccinates 302 
continued to increase up to 28 dpv. We also looked at the difference in titres of the individual sera 303 
against N75 and S96 (Fig 3e), as opposed to the differences between the two populations of titres; 304 
we found that the N75 vaccinates had a significantly higher titre against their homologous target at 305 
all time points measured (p≤0.0001), while S96 vaccinates have a higher titre against their 306 
homologous target at 21 and 28 dpv (p=0.018 and p=0.032, respectively). The neutralisation data 307 
therefore agree with the cELISA data that N75 vaccinates have a stronger antibody response (higher 308 
concentration and/or higher affinity of anti-PPRV antibodies) when measured against the 309 
homologous protein or virus, and show that the sera from these animals also have, at least initially, 310 
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 14 
a stronger antibody response even against a heterologous target. S96 vaccinates have a slower-311 
developing but less target-specific antibody response, with only a small difference between their 312 
recognition of homologous and heterologous targets. 313 
T cell response to vaccination 314 
Several approaches were tried to measure the development of PPRV-specific T cells after 315 
vaccination. Pools of peptides covering the PPRV H protein sequence (40) did not give any 316 
detectable T cell response in PBMCs from vaccinated goats (data not shown). In addition, non-317 
radioactive assays of cell proliferation ("Cell Trace") showed no detectable specific proliferation in 318 
response to peptides or total virus protein. We were able to detect PPRV-specific T cell 319 
proliferative responses in PBMCs from vaccinated animals using incorporation of 
3
H-thymidine 320 
after stimulation with either crude virus antigen or HI-virus, of which the former gave more 321 
pronounced PPRV-specific cell proliferation. Using this technique, the cell-mediated immune 322 
responses were studied in each group of vaccinated animals using both N75 and S96 virus proteins, 323 
i.e. both homologous and heterologous targets. 324 
Both groups of vaccinates showed an increased stimulated proliferation of PBMCs from 14 dpv, 325 
and the proliferation within each group was approximately the same whether stimulation was 326 
carried out with homologous or heterologous antigen (Fig 4a, b). A similar pattern was found using 327 
HI-virus as the stimulating antigen (Fig 4 c, d), although the proliferation observed was in general 328 
less. The stimulation of PBMCs from S96 vaccinates was clearly significantly increased over 0 dpv 329 
at 14, 21 and 28 dpv, whether the stimulus was homologous (S96 antigen) or heterologous (N75 330 
antigen) (p≤0.0003 for all comparisons). The response in N75 vaccinates was smaller and, perhaps 331 
due to the high level of background in samples taken prevaccination in this group of animals, not 332 
significantly different from 0 dpv at any subsequent time. However, when compared to 7 dpv, the 333 
PPRV-specific responses in the vaccinated animals were significantly increased at 14, 21 and 28 334 
dpv for homologous (N75) antigen (p=0.004, p=0.017 and p=0.016, respectively) and at 21 and 28 335 
dpv for the heterologous antigen (p=0.027 and p=0.017 respectively).  336 
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Comparing the two groups of vaccinates, the data in Fig 4 suggested that S96 vaccinates had a 337 
greater T cell proliferative response than the N75 vaccinates, regardless of the stimulating antigen; 338 
however, this only reached statistical significance at 28 dpv (p=0.0005 and p=0.045 for S96 and 339 
N75 antigens, respectively). 340 
These data showed that both vaccines induce some level of T cell-mediated response, but do not 341 
give any information as to which cell types are being induced. We therefore combined the labelling 342 
of lineage-specific T cell membrane proteins with intracellular staining (ICS) of IFN-γ (41), and 343 
used flow cytometry to identify the fraction of CD4
+
, CD8
+
 and CD4
-
CD8
-
 cells that were 344 
responding to PPRV antigens by increased production of IFNγ. The gating strategy used to define 345 
the three populations of cells is shown in Fig 2. For these studies, the best responses were obtained 346 
with live PPRV virus as the stimulating antigen, although the virus antigen preparation was also 347 
effective at stimulating PPRV-specific CD4
+
 cells. In all cases, the specific response was taken as 348 
the fraction of IFNγ+ cells in each group after subtracting the fraction of such cells seen after 349 
stimulation with a mock virus or antigen preparation. 350 
Both groups of vaccinates showed a clear development of PPRV-specific CD8
+
 cells (Fig 5); 351 
ANOVA showed no difference between vaccines, but a clear effect of dpv, although the stimulation 352 
was only statistically significant at 14 dpv (p=0.006). The CD8
+
 cells were not activated by 353 
incubation with the virus antigen preparation. The S96 vaccine also elicited PPRV-specific CD4
+
 T 354 
cells, with the numbers of reacting CD4
+
 cells in S96 vaccinates significantly increased at 14, 21 355 
and 28 dpv (p≤0.02 for all cases), and the same effect was seen for stimulation with either live virus 356 
or virus antigen. In cells from N75 vaccinates, there appeared to be a slight increase in the 357 
percentage of PPRV-specific CD4
+
 T
 
cells, but the change did not reach statistical significance. No 358 
change was seen in the numbers of IFNγ+ CD4-CD8- cells at any time (data not shown). 359 
Protection against challenge 360 
Groups of animals were challenged with one of 5 wild type viruses: PPRV/Ivory Coast/89 (lineage 361 
I); PPRV/Nigeria/76/1(lineage II); PPRV/Ghana/78 (lineage II); PPRV/Sudan/Sinnar/72 (lineage 362 
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III); PPRV/Iran/2011 (lineage IV). In each case, two unvaccinated goats were exposed to the 363 
challenge virus at the same time, to act as controls. The isolates used exhibited, in UK goats, a 364 
range of virulence, from very mild (Nigeria/76/1), moderate (Sudan/Sennar/72) to severe (Ivory 365 
Coast/89, Ghana/78, Iran/2011). In the case of the viruses causing severe disease, one or both of 366 
these unvaccinated control animals had to be euthanised before the termination of the experiment, 367 
as soon as the humane endpoint of this moderate protocol was reached. Rectal temperatures and 368 
clinical score profiles for these animals are given in Fig 6.  369 
None of the vaccinated animals showed any significant clinical signs at any stage; one or two 370 
animals in either group of vaccinates occasionally showed a slight congestion in the conjunctiva, or 371 
a transient cough, but this appeared to be an artefact of the closed environment of isolation units 372 
and unrelated to the study protocol, as we have observed this also in untreated animals. Notably, 373 
none of the vaccinated animals showed any detectable pyrexia (Fig 6a-e). No difference was seen in 374 
the temperature profiles or clinical scores of the two groups of vaccinates in any of the five 375 
challenge studies, although the unvaccinated control animals had clinical scores and temperature 376 
profiles that were significantly different from the vaccinates (p<0.05) in each case.  377 
We also carried out RT-qPCR for PPRV RNA in blood samples from animals in three of the 378 
vaccination/challenge studies (appropriate samples were not collected for the PPRV/Ivory Coast/89 379 
and PPRV/Iran/2011 challenges). These challenges represent mild, moderate and severe disease. 380 
PPRV RNA was not detected by this technique in samples from any group of vaccinates exposed to 381 
challenge with any of these three PPRV isolates (not shown), although PPRV RNA was clearly 382 
detected from 4-6 days post-challenge (dpc) onwards in samples from unvaccinated animals 383 
infected with PPRV/Ghana/78 or PPRV/Sudan/Sennar/72 (Fig 7b, c). Samples from unvaccinated 384 
controls infected with PPRV/Nigeria/76/1 were negative by RT-qPCR at all time points post-385 
challenge (Fig 7a). 386 
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Immune response following challenge with wild-type PPRV 387 
Antibody and T cell responses were assessed in vaccinates and control animals during the 14 days 388 
after infection with challenge virus. The unvaccinated control animals, as expected, developed a 389 
strong anti-N antibody response at 7 dpc (p<0.0001) and which did not increase significantly 390 
between 7 and 14 dpc (Fig 8a). Levels of anti-N antibody also increased in both groups of 391 
vaccinates at 7 dpc (p≤0.005), and also showed no significant increase between 7 and 14 dpc (Fig 392 
8a). Control animals also developed a strong anti-H response (Fig 8b); as observed for the primary 393 
antibody response to the vaccines, the anti-H response developed slightly more slowly, so the level 394 
of competing antibodies was significantly increased at 7 dpc (p=0.0013) and further increased at 14 395 
dpc (p<0.0001). Levels of anti-H antibody were also boosted in S96 vaccinates, showing a 396 
significant increase at 7 dpc (p=0.001), but no further increase at 14 dpc. In contrast, the N75 397 
vaccinates showed no significant change in anti-H antibody levels, perhaps because these were 398 
close to the maximum detectable by this assay before challenge. 399 
T cell proliferation assays (Fig 8c,d) showed that the surviving control animals developed a PPRV-400 
specific response by 14 dpc (p=0.0062), although samples could only be obtained from the control 401 
animals infected with PPRV/Nigeria/76/1 and PPRV/Sudan/Sennar/72, as the animals infected with 402 
PPRV/Iran/2011 had too few PBMCs at 7 dpc, and had been euthanised before 14 dpc. The 403 
proliferation assay was established after the completion of the experiments involving challenge with 404 
PPRV/Ivory Coast/89, and was not carried out for the animals in the PPRV/Ghana/78 challenge 405 
study due to time and sample restrictions. The N75 vaccinates showed a boost (p=0.0075) in 406 
proliferative responses to both viral antigens after challenge. The S96 vaccinates, on the other hand, 407 
showed no significant change in cell proliferation following challenge, which may reflect that the 408 
response seen in cells from these animals was already, prior to challenge, at the level reached by 409 
cells from the other groups after infection/boost (Fig 8c,d). There was no significant difference 410 
between the proliferative responses seen in any of the three groups of vaccinated/unvaccinated 411 
animals at 14 dpc. 412 
 o
n
 O
ctober 3, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 18 
Discussion 413 
We have shown that both N75 and S96 vaccine strains of PPRV gave complete clinical protection 414 
against challenge with field isolates representing all four genetic lineages of PPRV. Vaccinated 415 
animals demonstrated only occasional minor clinical signs such as slight congestion of ocular 416 
membranes, without discharge. Reddened ocular membranes occurred inconsistently both before 417 
and after challenge and might have been enhanced by the closed environment within the isolation 418 
facilities. In addition, as the goats in this study were of the white Saanen breed with a natural pallor, 419 
it could be that changes in membrane colour were more obvious than they would be in other breeds. 420 
In the light of these observations, this clinical sign on its own is probably not as useful a marker of 421 
PPRV infection in this breed as nasal discharge and elevated rectal temperatures. 422 
Where tested, neither group of vaccinates had detectable PPRV RNA in their blood, even when 423 
challenged with highly virulent PPRV/Ghana/78, infection with which gave rise to high levels of 424 
viral RNA in circulating blood in unvaccinated animals, as determined by RT-qPCR, providing 425 
further evidence of the general cross-protection provided by both vaccines. An important additional 426 
observation from these studies was that a very mild strain of PPRV, the Nigeria/76/1 isolate, had no 427 
detectable viral RNA in blood samples from unvaccinated challenge control animals. This means 428 
that an animal infected with such a virus may not be identified as PPRV-infected by routine testing. 429 
Very mild rinderpest virus isolates were known to circulate during the later stages of the rinderpest 430 
eradication campaign (e.g. 42, 43, 44), and sometimes went undetected because of their low 431 
pathogenicity. It will be important to determine if similar PPRV strains are transmitted, and may 432 
therefore be circulating undetected in some populations. 433 
In terms of the specific immune responses following vaccination, both vaccines induced both 434 
antibody and T cell-mediated responses. Whilst the N75 vaccine appeared to be superior at eliciting 435 
neutralising antibodies (particularly against its homologous virus), the S96 vaccine seemed to be 436 
better at inducing T cell responses, particularly PPRV-specific CD4
+
 cells, as seen in the IFN-γ 437 
assay and implied by the proliferation assay data. The virus neutralisation tests (VNTs) gave a more 438 
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balanced picture than the cELISAs, since they give an indication of the levels of neutralising (and 439 
therefore presumably protective) antibodies present in serum, whilst the cELISAs measure the 440 
presence of a particular subset of anti-PPRV antibodies which, in the case of anti-N protein 441 
antibodies, are unlikely to be protective, since anti-N antibodies are not neutralising. It is clear from 442 
the studies here that vaccination with N75 gave rise to high titre antibodies directed against 443 
PPRV/Nigeria/75/1-specific neutralising epitopes, since there was relatively little difference in the 444 
titres of the two groups of sera against S96, but a very large difference in titres against N75. This 445 
suggests that both vaccines elicit good titres of antibodies that are generally cross-protective, but 446 
there is an additional strong epitope on the N75 vaccine strain. It would be interesting to determine 447 
if this epitope is specific to the Vero-cell adapted vaccine or is common to other lineage II viruses. 448 
Several antigens were assessed for their ability to stimulate the production of IFN-γ for the 449 
intracellular cytokine staining assay, but by far the most successful stimulant for PPRV-specific 450 
IFN-γ production was live PPRV. Both vaccines induced CD8+ T cells that produced IFN-γ in 451 
response to live virus stimulation. These data suggest efficient processing of antigen into the MHC 452 
class I presentation pathway, which in turn suggests that PPRV is infecting a subset of cells within 453 
the PBMC population, presumably cells expressing the PPRV receptor SLAM/CD150. It would be 454 
interesting to explore whether this is indeed the case and which cells are infected. Morbilliviruses, 455 
particularly the attenuated vaccine strains, infect PBMCs relatively poorly, unless expression of 456 
SLAM is first stimulated by incubation with mitogens such as Concanavalin A (45-48). While both 457 
vaccines elicited similar numbers of PPRV-specific CD8
+
 T cells, it would appear from the data 458 
presented here that the S96 vaccine is better than the N75 vaccine at eliciting PPRV-specific CD4
+
 459 
T cells. These CD4
+
 cells are most likely the underlying reason for the difference in the 460 
proliferation assay data between S96 and N75 vaccinates, where cells from the former proliferated 461 
significantly more strongly than cells from the latter. This difference between the detailed immune 462 
response to the two vaccines, of course, may be dependent on the genotype of the hosts, since 463 
differences in genotype are known to affect the levels of specific types of immune responses in 464 
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measles virus vaccination (e.g. 49, 50, 51). However, it is of note that these differences in the 465 
details of the response did not affect the protection from disease. In our studies, neither the 466 
proliferation assay nor the ICS assay showed any significant difference in the responses to 467 
heterologous or homologous antigens, suggesting the dominant epitopes are common to at least 468 
both lineage II and lineage IV. The presence of strong epitopes common to all lineages provides a 469 
mechanism for the broad cross-protection seen between PPRV strains, and indeed between PPRV 470 
and rinderpest virus (26, 52). 471 
One of the primary arguments for using lineage-specific vaccines is the fear that a vaccine could 472 
revert to virulence and lead to multiple genetic lineages of PPRV circulating in the field (13). This 473 
seems an unfounded concern as the live attenuated vaccines have been tested and used for decades 474 
in multiple countries with no adverse effects, including no adverse events in pregnant animals (13, 475 
53, 54). Indeed, a greater risk arises from the introduction of new vaccines that may not have been 476 
so well characterised. A more realistic concern is the creation of hybrid lineage viruses through 477 
recombination between co-circulating viruses. Studies using computer analysis of genome 478 
sequences have suggested that recombination occurs between homologous paramyxoviruses (see 479 
(55) and references therein). Such recombination may eventually be shown also for PPRV, if an 480 
animal is infected with two significantly different wild type viruses. The studies reported here 481 
demonstrate that there are conserved protective epitopes common to all lineages of the virus, and 482 
which will therefore also be present on any inter-lineage recombinant, meaning any such 483 
recombinant will also be susceptible to the immune protection provided by either of these vaccines. 484 
While the N75 and S96 vaccine strains are effective, they are derived from viruses isolated 43 and 485 
22 years ago, respectively, and there may be significant genetic drift between these strains and those 486 
circulating now. In the case of Newcastle disease virus (NDV), which is also a paramyxovirus, and 487 
causes a widespread and economically important disease of chickens, turkeys and other birds, the 488 
established live attenuated virus vaccines are also now many decades old. Whilst these vaccines are 489 
effective at preventing disease caused by modern strains of the virus when administered correctly 490 
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(56-59), they are not as effective at preventing virus shedding as vaccines that are genotypically 491 
matched to the wild type challenge virus (58-63). Shedding is particularly important in the case of 492 
this avian disease, as many wild species of birds are also susceptible and can transmit the virus. The 493 
situation may be different in the case of a disease affecting sheep and goats, which are not as 494 
intensively housed, and where there does not appear to be a wildlife reservoir. It has been shown 495 
that N75 vaccine does not completely prevent shedding, as represented by detectable viral RNA in 496 
nasal, ocular and rectal swabs, from challenged animals (64); however, that study did not measure 497 
shedding of infectious virus, and the fact that this lineage II vaccine has been successfully used in 498 
both China and Morocco to eradicate disease caused by lineage IV viruses suggests that, at the 499 
moment, the existing PPRV vaccines are sufficiently cross-protective to prevent transmission in 500 
vaccinated animals.  501 
We have shown here that two vaccine strains, one originating in Nigeria and the other originating in 502 
India, are each capable of protecting goats against infection with field strains of any genetic lineage, 503 
including a recent isolate, confirming that any properly characterised live attenuated PPRV vaccine 504 
that is available can be utilised to protect livestock, irrespective of the local circulating strains. It is 505 
clear, however, that it will be important for those involved in the current efforts to control and 506 
eventually eradicate PPR to continue to monitor the effectiveness of the vaccines in use, and better 507 
information on the shedding of infectious virus (as opposed to virus antigen or RNA) by vaccinated 508 
animals would be useful. 509 
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Figure legends 702 
Figure 1 Phylogenetic tree of PPRV showing lineages I to IV 703 
A phylogenetic tree showing the genetic distances between the available full-length PPRV genomes 704 
was calculated as described in Methods using MEGA6. The tree with the highest log likelihood is 705 
shown, with the percentage of trees in which the associated taxa clustered together in the bootstrap 706 
(500 replicates) shown next to the branches. The tree is drawn to scale, with branch lengths 707 
measured in the number of substitutions per site; the scale bar shows 0.02 substitutions per site. The 708 
labels at the ends of the branches show the accession number of the genome sequence and the 709 
country and year of the virus's isolation. The clades considered as lineages I to IV are shown on the 710 
right. 711 
Figure 2 Gating strategy for identifying PPRV-specific CD4
+
 and CD8
+
 T cells PBMCs were 712 
stimulated with live virus or antigen for 18 hours and then for an additional 6 hours in the presence 713 
of the Golgi transport inhibitor Golgi-Plug. The cells were then labelled with anti-CD4 and anti-714 
CD8 mAbs and a live/dead stain, after which they were fixed/permeabilised and labelled with anti-715 
IFN-γ. The numbers of labelled cells were determined by flow cytometry using a MACSQuant and 716 
the data analysed with FlowJo X. An example dataset is shown for PBMCs taken from an animal 717 
vaccinated with S96 at 14 dpv and stimulated with S96 virus. The cells were gated successively for 718 
(a) singlets, (b) lymphocytes, (c) live cells and then (d) by the presence or absence of the surface 719 
markers CD8 and CD4. The percentage IFN-γ+ cells was obtained for (e) CD8+ cells, (f) CD4+ 720 
cells, and (g) CD4
-
CD8
-
 cells.  721 
Figure 3 Antibody response in goats to PPRV vaccines Goats were vaccinated with N75 or S96 722 
and serum samples were taken at 0, 7, 14, 21 and 28 dpv. Sera taken at all time points were assayed 723 
for antibodies to (a) the PPRV N protein and (b) the PPRV H protein using available cELISA kits. 724 
Sera taken at 14, 21 and 28 dpv were additionally assayed for neutralisation of PPRV; neutralising 725 
titres were determined against (c) N75 vaccine virus and (d) S96 vaccine virus. The differences in 726 
titres (titre against N75 virus – titre against S96 virus) for each individual serum was calculated and 727 
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these differences are plotted in (e). Note that the manufacturer's recommended calculation for the N 728 
protein cELISA kit (a) gives values that decrease as the amount of anti-N antibody increases 729 
(percent of negative control), while that for the H protein cELISA kit (b) gives values that increase 730 
as the amount of competing antibody increases (percent inhibition of binding of monoclonal 731 
antibody). The data are presented as box-and-whisker plots, in which the bars span the minimum 732 
and maximum values and the box shows the range from the 1
st
 to the 3
rd
 quartile. The central 733 
horizontal line in each box shows the median value. The number of samples assayed at each time 734 
point shown were (a) 25/19/25/19/24, (b) 15/10/15/10/14, (c-e) 15/15/15. 735 
Figure 4 T cell proliferative responses in goats after PPRV vaccination Goats were vaccinated 736 
with N75 or S96 vaccine and PBMCs were prepared from heparinized blood at 0, 7, 14, 21 and 28 737 
dpv. Proliferative responses were measured by incorporation of 
3
H-thymidine as described in 738 
Methods. Proliferation was stimulated with (a) protein from cells infected with N75, (b) protein 739 
from cells infected with S96 virus, (c) heat-inactivated preparations of N75 virus or (d) heat-740 
inactivated preparations of S96 virus. The Stimulation Index (SI) was measured as the proliferation 741 
relative to that seen in PBMCs incubated with (a, b) protein from uninfected cells or (c, d) mock 742 
viral preparations from uninfected cells. The data is presented as a stacked bar plot showing the SI 743 
for each animal, using different shades to delineate the contribution of different animals to the 744 
cumulative SI for the group of vaccinates at that time point. Data from animals vaccinated with S96 745 
(n=15) are in blue shades, data from animals vaccinated with N75 (n=14) in red shades. To allow 746 
for the differing number of animals in each group, the values have been scaled before plotting by 747 
dividing by the number of animals in the group. 748 
Figure 5 PPRV-specific IFN-γ-producing CD4+ and CD8+ T cells in goats following PPRV 749 
vaccination Goats were vaccinated with N75 or S96 vaccine and PBMCs were prepared from 750 
heparinised blood at 0, 7, 14, 21 and 28 dpv. T cell subtypes responding to live PPRV virus or 751 
inactivated PPRV antigen by producing IFN-γ were determined in triplicate by intracellular 752 
labelling of IFN-γ and flow cytometry as described in Methods. The gating strategy for identifying 753 
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IFNγ-positive CD8+ or CD4+ T cells was as shown in Fig 2. The percent of total CD4+ T cells (a, 754 
c) or CD8
+
 T cells (b, d) that responded to PPRV was calculated by subtracting the percent 755 
observed after stimulation with mock antigen or virus preparations. The graphs show the mean 756 
specific percentage of IFN-γ producing cells observed in response to the indicated stimulation of 757 
PBMCs from five N75 (a, b) and five S96 (c, d) vaccinates. Error bars show S.E.M. 758 
Figure 6 Rectal temperatures and clinical scores in experimental animals after challenge with 759 
wild type viruses. The rectal temperatures (a-e) and clinical scores (f-j) of each experimental 760 
animal were recorded daily after challenge with the indicated wild type virus. Data from individual 761 
unvaccinated animals are shown in black, from S96 vaccinates in blue and from N75 vaccinates in 762 
red. 763 
Figure 7 Detection of PPRV genome by RT-qPCR in unvaccinated controls after challenge. 764 
EDTA-blood was collected every second day following challenge and 1 ml aliquots frozen for later 765 
analysis. PPRV RNA was detected using the one-tube RT-qPCR technique (Methods). Points are 766 
the mean of duplicate PCR reactions, results are displayed as 45 - Ct value. Graphs depict the 767 
results for mock vaccinated controls infected with (a) PPRV/Nigeria/76/1, (b) PPRV/Ghana/78, or 768 
(c) PPRV/Sudan/Sennar/72. None of the vaccinated animals tested had detectable PPRV RNA in 769 
any blood sample taken post-challenge (data not shown). 770 
Figure 8 Immune responses in goats after challenge with PPRV Goats vaccinated with live 771 
PPRV vaccines were challenged 28 dpv, along with unvaccinated controls; heparinised blood and 772 
serum was collected from each animal at 0, 7 and 14 dpi. (a, b) Serum samples were assayed for 773 
antibodies to (a) the PPRV N protein and (b) the PPRV H protein using available cELISA kits. The 774 
N protein cELISA was applied to all samples from all 5 challenge studies; the H cELISA was only 775 
applied to samples from animals challenged with PPRV/Ivory Coast/89, PPRV/Nigeria/76/1 and 776 
PPRV/Iran/2011. The number of serum samples assayed at the time points shown were: (a) 777 
25/25/20 for vaccinates and 8/7/4 for controls; (b)14 at each time point for N75, 15 at each time 778 
point for S96 vaccinates and 6/6/3 for controls. The data in (a) and (b) are presented as box-and-779 
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whisker plots, in which the bars span the minimum and maximum values and the box shows the 780 
range from the 1
st
 to the 3
rd
 quartile. The central horizontal line in each box shows the median 781 
value. (c, d) PBMCs were prepared from the heparinised blood and proliferation of cells in response 782 
to PPRV antigen was assayed as described for Fig 4. Proliferation was stimulated with (c) protein 783 
from cells infected with N75 or (d) protein from cells infected with S96 virus. The Stimulation 784 
Index (SI) was measured as the proliferation relative to that seen in PBMCs incubated with protein 785 
from uninfected cells. The data is presented as a stacked bar plot showing the SI for each animal, 786 
using different shades to delineate the contribution of different animals to the cumulative SI for the 787 
group of vaccinates at that time point. Data from individual animals vaccinated with N75 are in red 788 
shades, data from individual animals vaccinated with S96 in blue shades and data from individual 789 
unvaccinated animals in grey shades. To allow for the varying number of animals in each group, the 790 
values have been scaled before plotting by dividing by the number of animals in each group. Data 791 
was obtained for samples from animals challenged with PPRV/Nigeria/76/1 and 792 
PPRV/Sudan/Sennar/72; data was also obtained for the vaccinates challenged with 793 
PPRV/Iran/2011, but not from unvaccinated animals infected with this virus, which had too low 794 
white cell count at 7 dpi for the assay to be carried out, and were euthanised before 14dpi. The 795 
number of PBMC samples assayed at each time was 14/9/12 for N75 vaccinates, 15/10/14 for S96 796 
vaccinates and 4/4/4 for unvaccinated animals. Note that the data from 0 dpc is that shown in Figs 3 797 
& 4 as 28 dpv, and is included here for comparison. 798 
 799 
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